<DOC>
	<DOCNO>NCT01351571</DOCNO>
	<brief_summary>This observational study evaluate safety efficacy Avastin ( bevacizumab ) combination interferon alpha-2a first-line treatment patient advance and/or metastatic renal cell carcinoma . Data collect patient 4 year .</brief_summary>
	<brief_title>An Observational Study Avastin ( Bevacizumab ) Combination With Interferon Alpha-2a First-Line Treatment Patients With Advanced and/or Metastatic Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Advanced and/or metastatic renal cell carcinoma Receiving firstline treatment Avastin interferon alpha2a accord standard care current local label At least one measurable nonmeasurable lesion accord RECIST criterion Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Adequate bone marrow , renal liver function Contraindications Avastin and/or interferon alpha2a per local label</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>